LAM-001 for Pulmonary Hypertension
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you be on a stable dose of your current pulmonary hypertension medication for at least 30 days before starting. If you are on any other medications, the protocol does not specify if you need to stop them, but it's best to discuss with the trial team.
What data supports the effectiveness of the drug LAM-001 for pulmonary hypertension?
What is the purpose of this trial?
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
Eligibility Criteria
Adults diagnosed with pulmonary hypertension who can walk a certain distance and are already on stable PAH therapy may join. They must not have had major surgery or other clinical trials recently, no active cancer in the past 5 years, no severe heart issues, and their liver and kidney functions should be within specific limits. Women of childbearing age must use contraception; men must agree to use condoms.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard of care plus LAM-001 once daily for 24 weeks
Extension
Participants with a favorable benefit-risk profile continue receiving LAM-001 for up to 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LAM-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
OrphAI Therapeutics
Lead Sponsor
AI Therapeutics, Inc.
Lead Sponsor